Atlas Trials

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Clinical trial NCT03745170 · COMPLETED

Trial details

NCT number
NCT03745170
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Gastric Cancer
Start date
2018-12-19
Primary completion
2021-06-20
Enrollment
650

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.